Chinese medical firms queue up to invest in AI and chip funds
A report by VCBeat (republished by 36Kr and TMTPost) says that after Jiu'an Medical proved out a "medical main business plus tech investment" model, listed medical companies including Yuwell Medical, Mindray-like diagnostics firm Mingde Biotech, Intco Medical, Yifan Pharmaceutical and Amoytop Biotech have collectively subscribed to funds whose investment focus is AI and semiconductors. Jiu'an Medical's portfolio reportedly includes Moonshot AI, MetaX, StepFun and Zhengxing Innovation, and its net profit rose 233.66% year on year in the first half of 2026; Yuwell Hong Kong put in HK$94.9 million for shares in CFTC Summit Fund SPC vehicles and planned to commit up to RMB 500 million to a fund managed by Sino IC Capital. The report adds that most listed medical firms still stay in healthcare, and industry figures warn that AI and semiconductor asset valuations are already high, so raising exposure now may not repeat Jiu'an's timing.
Healthcare listings are becoming cross-industry backers of AI and chip funds while using the investments to source technology for their own products, an example of how AI capital is broadening beyond tech investors.